Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 17, Issue 12, 2017, Pages 897-901

  Assi, Rita ^a   Kantarjian, Hagop ^a   Short, Nicholas J ^a   Daver, Naval ^a   Takahashi, Koichi ^a   Garcia Manero, Guillermo ^a   DiNardo, Courtney ^a   Burger, Jan ^a   Cortes, Jorge ^a   Jain, Nitin ^a   Wierda, William ^a   Chamoun, Salim ^a   Konopleva, Marina ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALL; Blinatumomab; CML; Philadelphia chromosome; Relapsed refractory

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL1 PROTEIN; BLINATUMOMAB; BOSUTINIB; DASATINIB; MERCAPTOPURINE; METHOTREXATE; PONATINIB; PREDNISONE; STEROID; TOCILIZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; BISPECIFIC ANTIBODY; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ARTICLE; BLAST CELL CRISIS; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONFUSION; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPTIC STATE; FOLLOW UP; HEADACHE; HUMAN; LEUKEMIA RELAPSE; MEDIAN SURVIVAL TIME; MEMORY DISORDER; MENTAL DISEASE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PNEUMONIA; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SEIZURE; SHORT TERM MEMORY; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEROID THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85029514413     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2017.08.101     Document Type: Article

References (21)

1. Gökbuget, N., Kneba, M., Raff, T., et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120 (2012), 1868–1876.
2. Ribera, J.M., Oriol, A., Morgades, M., et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol 32 (2014), 1595–1604.
3. Short, N.J., Jabbour, E., Sasaki, K., et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128 (2016), 504–507.
4. Thomas, D.A., Faderl, S., Cortes, J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004), 4396–4407.
5. Ravandi, F., O'Brien, S.M., Cortes, J.E., et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121 (2015), 4158–4164.
6. Jabbour, E., Kantarjian, H., Ravandi, F., et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16 (2015), 1547–1555.
7. Sasaki, K., Jabbour, E.J., Ravandi, F., et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 122 (2016), 3650–3656.
8. Jabbour, E., O'Brien, S., Ravandi, F., et al. Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125 (2015), 4010–4016.
9. Mack, M., Riethmüller, G., Kufer, P., A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 92 (1995), 7021–7025.
10. Topp, M.S., Kufer, P., Gökbuget, N., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29 (2011), 2493–2498.
11. Topp, M.S., Gökbuget, N., Stein, A.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16 (2015), 57–66.
12. Topp, M.S., Gökbuget, N., Zugmaier, G., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120 (2012), 5185–5187.
13. Gökbuget, N., Dombret, H., Bonifacio, M., et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE (R)) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood, 124, 2014, 379.
14. Gökbuget, N., Dombret, H., Bonifacio, M., et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood, 126, 2015, 680.
15. Martinelli, G., Dombret, H., Chevallier, P., et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). [abstract] Blood, 126, 2015, 679.
16. Appelbaum, F.R., Rosenblum, D., Arceci, R.J., et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109 (2007), 1810–1816.
17. Luthra, R., Sanchez-Vega, B., Medeiros, L.J., TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol 17 (2004), 96–103.
18. Jones, D., Thomas, D., Yin, C.C., et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113 (2008), 985–994.
19. Ravandi, F., Jorgensen, J.L., O'Brien, S.M., et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172 (2016), 392–400.
20. Cortes, J.E., Ibarz, J.P., Coutre, P.L., et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood, 124, 2014, 3135.
21. Stein, A.S., Topp, M.S., Kantarjian, H.M., et al. Treatment with anti-CD19 BiTE blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) post-allogeneic hematopoietic stem cell transplantation. [abstract] Blood, 126, 2015, 861.